An Asia-based investment firm backed by a large bank is managing a US$60M healthcare fund raised in 2014. The firm invests in several sectors across healthcare. The firm generally participates in Series A or B rounds and prefers a clear exit in less than 5 years. The firm is open to both leading and co-investing. Typical equity investments range from US$2-10M. The firm currently focuses 60% on regional-based deals and 40% on China- and US-based deals.
The firm considers therapeutics and medical devices. Within therapeutics, the firm is open to all modalities including small molecules, biologics, cell therapy and gene therapy with a focus on cancer therapies. The firm would also consider R&D services, healthcare services, and healthcare IT products such as EMR management software. The firm seeks to invest in venture stage companies in Series A or B rounds.
The firm prefers to back entrepreneurs with a successful track record. The firm typically requests a board seat in their portfolio company.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Leave a Reply